The Team
Jeff founded Apeiron Partners in 1996 and has structured a variety of strategic alliances, financings and, particularly, corporate spin-outs and other NewCos. Jeff has designed and completed five such NewCos to date, including Targacept, Inc. (NASD:TRGT) from the R.J. Reynolds Tobacco Company, Artisan Pharma, Inc., Ketocytonyx from BTG, Plc., QED Solutions, Inc., and KBI BIoPharma, Inc. from Kinetic BioSystems, Inc.. In addition, Jeff worked extensively on the design and structuring of BioCritica, Inc. from Eli Lilly & Company.
Between 2005 – 2009, Jeff advised Asahi Kasei Pharma Corporation in establishing and financing Artisan Pharma, Inc., involving a product that is now marketed in Japan (ART 123). As its founding CEO, Jeff raised over $50 million, built a full operational team and led all strategic and tactical initiatives.
Between 2003 – 2006 Jeff and the Apeiron team were selected as advisors to Z-Cube s.r.l., the corporate venture arm of Zambon Group, s.r.l., the largest privately-held pharmaceutical company in Italy, to assist it in establishing and investing a €60 million fund. As a result, he played a significant role in identifying and structuring investments in Suppremol, GmbH, Pharmeste, s.r.l., and others.
Prior to Apeiron, Jeff worked for Medical Science Partners (MSP), a Harvard-affiliated venture capital fund, and was intimately involved in the business development of a number of its portfolio companies. These firms spanned start-ups through publicly-held companies and included deCode Genetics, ICAgen, Diatide, Zycos and Oravax, amongst others.
Prior to MSP, Jeff was Executive Director of Business Development for the life sciences group of a trading company affiliate of the Bank of Tokyo-Mitsubishi, where he was responsible for a number of strategic alliances between U.S. and Japanese firms.
Jeff received his M.D. from Rush Medical College in Chicago and his MBA from the University of Chicago.
jeffrey.wager@apeironpartners.com
Direct: +1 508.400.1856
Joseph Wager is a Managing Director of Apeiron Partners. Prior to working at Apeiron Partners, Joe held strategic consulting positions spanning nearly 20 years in leading firms such as Medicus/Publicis, IBM/The Wilkerson Group, CSC Healthcare, EDS/A.T. Kearney and MDS. Joe was also VP of Research and Business Development for Prescription Solutions, a Pacificare/United Healthcare Company.
Throughout his career, Joe has focused on strategy, research & development, operations, corporate finance, marketing and sales within the bio-pharmaceutical and medical device sectors. He has worked on both a domestic and international level, having lived on two continents in the process. He has worked on a wide variety of business development and strategic initiatives for a spectrum of clients ranging from industry, academia and government.
Mr. Wager holds a M.B.A. from the University of Chicago, a M.S. in Neurobiology from the University of Illinois and a B.S. in Hospital Administration from Southern Illinois University. In addition, Mr. Wager has completed numerous post-graduate courses in diverse areas relating to the life sciences industry, including consulting frameworks and clinical drug development. He is also a co-founder of Pferde Farm LLC and The Magic Saddle, a 501(c)3 providing services to children with special needs.
Direct +1 847.840.8278
Peter is the Chief Financial and Chief Compliance Officer for Commonwealth Pharma Securities LLC, the SEC and FINRA registered broker dealer of Apeiron Partners LLC. Peter began his professional career with the U.S. Securities and Exchange Commission and held a number of senior level positions with the SEC, primarily involving the regulation of broker dealers, investment advisers, investment companies and transfer agents. Peter participated in a number of significant investigative matters while at the SEC and he has assisted the Department of Justice’s criminal investigations involving regulated entities. Following the SEC, Peter was the General Counsel, Chief Compliance Officer and CFO for Leerink Swann & Company, a Boston based health care investment bank. Peter is frequently an expert in securities litigation and arbitrations.
Peter has a BS from Boston College and a JD from Suffolk University Law School. Peter holds the FINRA Series 7, 24, 28 & 79 licenses.
peter.flynn@apeironpartners.com
Tel. 617.367.0099
Fred contributes as a Principal of our broker-dealer, Commonwealth Pharma Securities. For the past 14 years, Fred has been engaged in strategy, finance, and business development within the biotech and pharmaceutical industry. Fred has provided strategic advice to early and mid-stage ventures also has also designed and implemented financings, key technology licenses, and partnership deals for clients of Apeiron Partners. Fred also performed biotechnology equity research at Needham & Company and business development for portfolio companies of Schooner Capital.
Fred holds a Ph.D. in Molecular Genetics from Ohio State University and has earned the Chartered Financial Analyst designation.
Fred can be reached at fred.meyer@apeironpartners.com
Glenn serves Apeiron as its CFO. In this role, and in addition to his internal accounting work, he works closely with Apeiron’s start-ups and entrepreneurs, regularly building sophisticated, interactive financial models that enable better decision-making at the executive level.
In the mid-late’90s, Glenn served as Director of Finance for Medical Science Partners, a Harvard sponsored, life science venture capital firm. During his tenure, he developed the firm’s consulting department. In 1998, he founded Globe Matrix Consulting as a spin-off of MSP’s consulting department. Globe Matrix Consulting provided accounting and finance services to incubators/start-ups funded by various venture capital firms. Glenn has also served as Interim Director of Finance for several reputable venture capital firms such as Spectrum Equity, Brook Venture Fund and Arctaris Capital Partners. He has also worked extensively with U.S.-based companies with European operations, and on international mergers and system implementation projects.
Glenn is a graduate of Hartwick College, and holds an MBA in International Business and Entrepreneurship from Thunderbird, School of Global Management. He is also a Certified Public Accountant.
Glenn can be reached at glenn.baker@apeironpartners.com